Immunovant, Inc. IMVT

IMVT Company Overview

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. The company’s core scientific platform centers on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in recycling immunoglobulin G (IgG) antibodies in the body. By reducing circulating pathogenic IgG antibodies, Immunovant aims to treat a range of autoimmune conditions driven by autoantibody activity. The company operates within the biotechnology and immunology sectors and primarily targets specialty autoimmune indications with significant unmet medical need.

Immunovant’s primary product candidate is batoclimab, an FcRn inhibitor investigated across multiple autoimmune diseases. The company has also advanced IMVT-1402, a next-generation FcRn inhibitor designed to potentially improve safety and dosing flexibility. Immunovant was formed in 2018 as a subsidiary of Roivant Sciences Ltd. and later became a publicly traded company through a business combination with a special purpose acquisition company. Its strategic positioning is tied to its focused autoimmune pipeline, access to Roivant’s drug-development ecosystem, and specialization in FcRn-mediated immunology therapies.